KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Net Income	-210.15	-183.44	-126.64	-92.91	-82.34	-46.24
Depreciation & Amortization	1.27	0.94	0.82	0.72	0.56	0.54
Stock-Based Compensation	19.77	12.29	21.92	9.92	11.09	7.12
Other Adjustments	3.45	2.27	-0.49	-0.41	4.88	0.07
Change in Receivables	7.95	7.25	8.18	-2.32	-5.2	7.46
Changes in Inventories	-0.67	-	-	-	-	-
Changes in Accounts Payable	12.51	-4.97	4.32	1.11	1.69	0.15
Changes in Accrued Expenses	-15.25	14.43	3.21	1.93	0.47	0.98
Changes in Unearned Revenue	11.2	10.56	-	-	-	-
Changes in Other Operating Activities	-4.41	-12.23	-0.54	6.69	-9.28	-0.24
Operating Cash Flow	-152.6	-152.91	-89.23	-75.26	-78.13	-30.17
Capital Expenditures	-2.3	-0.43	-0.04	-1.2	-0.93	-0.08
Purchases of Intangible Assets	-0.63	-0.5	-0.4	-	-	-
Purchases of Investments	-155.99	-30.57	-189.23	-98.25	-136.92	-201.21
Proceeds from Sale of Investments	115.9	122.52	104.96	140.86	195.71	53.64
Investing Cash Flow	-43.01	91.02	-84.72	41.42	57.86	-147.65
Issuance of Common Stock	3.24	61.69	150.71	58.12	1.58	212.12
Net Common Stock Issued (Repurchased)	3.24	61.69	150.71	58.12	1.58	212.12
Other Financing Activities	21.92	98.04	-	-	-	-
Financing Cash Flow	263.99	159.73	150.71	58.12	1.58	212.12
Effect of Exchange Rate Changes on Cash and Cash Equivalents	5.62	2.64	-1.21	1.24	-1.17	0.51
Net Cash Flow	73.99	100.48	-24.45	25.51	-19.86	34.8
Free Cash Flow	-154.9	-153.34	-89.27	-76.46	-79.07	-30.25
Free Cash Flow Per Share	-2.88	-3.09	-2.43	-2.74	-3.23	-1.58
Levered Free Cash Flow	-181.08	-175.15	-118.88	-83.66	-89.83	-44.9
Unlevered Free Cash Flow	-181.14	-183.25	-132.68	-101.62	-104.1	-56.58

Updated May 14, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q